no consistent abnormality apart from a moderate increase in plasma cells. Reviewing the literature, these authors found that megaloblastosis had been reported only once in patients with rheumatoid arthritis (Marmont, 1948) . Partridge and Duthie (1963) found an incidence of macrocytic anaemia attributed to vitamin B12 deficiency in 1-38 per cent. of 2,544 patients with rheumatoid arthritis, as compared to an incidence of 0 -27 per cent. in controls. Other authors (Forshaw, 1963 ; Mollin, Waters, Gough, and Read, 1963) suggested that folic acid deficiency may have been a causal factor. Gough, McCarthy, Read, Mollin, Deller, Urban, Ibbotson, Horwood, Milazzo, and Robson (1966 (Ropes, Bennett, Cobb, Jacox, and Jessar, 1959 Duthie, Thompson, Weir, and Fletcher (1955) Folic acid metabolism was studied in five rheumatoid patients on admission and after a remission in disease activity had been induced by a 4-week course of ACTH (20 i.u. intramuscularly daily for 2 weeks and 10 i.u. daily for the remaining 2 weeks). All patients had generalized joint involvement and systemic manifestations of the disease on admission, and none received folic acid during the period in hospital.
Follow-up Study
Seven rheumatoid patients, none of whom received folic acid during the period of study, were recalled 3 months or more after discharge from hospital and their plasma and erythrocyte folate levels were re-estimated.
Methods
Collection of Blood and Preparation of Samples 40 ml. blood were obtained by venepuncture from fasting subjects. 2 ml. were delivered into a sequestrene bottle for determination of the haematological indices, and 18 ml. were put into a universal container and allowed to clot for 2 hours at room temperature before the serum was separated and stored at -20°C. for vitamin B12 estimation. The remaining 20 ml. were added to a heparinized container from which plasma was separated by centrifugation and stored at -20°C. with 10 mg. dry ascorbic acid/ml. for folate estimation.
The packed erythrocytes were washed three times with acid citrate dextrose (ACD) and 0-8 ml. samples were added to 1*5 ml. aliquots of patient and control plasma respectively. The control plasma was obtained from the same donor throughout the study and stored at -200 C. Three 0 4 ml. volumes of each product, with 10 mg. dry ascorbic acid added, were stored at -200 C. On the day of the assay samples were thawed at room temperature, 1-6 ml. distilled water was added to each, and they were left for a further 15 minutes at room temperature. 18 ml. of 0-1 M phosphate buffer pH 6 containing 150 mg. per cent. ascorbic acid were then added and the proteins precipitated by autoclaving at 15 lb./sq. in. for 5 minutes.
Plasma and Erythrocyte Folate
The folate content of plasma and erythrocytes was determined by the method of Waters and Mollin (1961) , except that autoclaved ascorbate-phosphate buffer was added to standard tubes.
Serum Vitamin BL2
The vitamin B12 content of serum was determined by the method of Anderson (1964) . The range of serum vitamin B12 concentration in normal controls is 150-1000 twg./ml.
Folic Acid Absorption and Clearance
The absorption of folic acid was measured by the method of Girdwood (1953 Girdwood ( , 1960 , and its clearance from the plasma by the method of Chanarin, Mollin, and Anderson (1958) .
Bone Marrow Examination
May-Grunwald-Giemsa stained slides of bone marrow were examined by an experienced haematologist (S. H. Davies) and one of us (A.O.), and were classified as normoblastic, early megaloblastic, or frankly megaloblastic. Classification was based on the overall marrow picture particularly affecting the erythroid series. Patients whose marrow showed only the presence of a few giant metamyelocytes were not included in the megaloblastic group.
Urinary Formiminoglutamic Acid (FIGLU) and Urocanic Acid Combined urinary FIGLU and urocanic acid was measured by the spectrophotometric method of Chanarin and Bennett (1962) in an 8-hour collection of urine after an oral dose of 15 g. histidine. Urocanic acid was also determined separately after destroying FIGLU by autoclaving the urine at an alkaline pH.
Sensitized Sheep Cell Titre
The sensitized sheep cell titre (SSCT) for rheumatoid factor was performed by the method of Ball (1952) , modified by the use of M.R.C. haemagglutination plates in place of test tubes.
Other Haematological Indices
The haematological methods were those described by Dacie and Lewis (1963) .
Results

Plasma Folate Levels
The plasma folate levels for healthy controls, patients with megaloblastic anaemia due to folic acid deficiency, and patients with rheumatoid arthritis are compared in Fig. 1 (opposite). The range for normal controls is 2-6 to 10 4 m,ug./ml. (mean of 4 -7). Patients with megaloblastic anaemia had levels of less than 2 0 mutg./ml. In the rheumatoid arthritis group, 24 cases (65 per cent.) had subnormal levels, and in seventeen of these (46 per 
Bone Marrow Morphology
The bone marrow was normoblastic in 29 (78 per cent.) of the rheumatoid patients. The remaining eight cases showed early megaloblastic change. Table II shows that only five of these cases had plasma folate levels within the range found in megaloblastic anaemia due to folate deficiency, and that four of these also had subnormal erythrocyte folate levels.
Folic Acid Clearance
This was measured in eight of the rheumatoid patients (Fig. 4) . Erythropoiesis was normoblastic in all patients studied (Table III Table IV shows that ten out of twelve patients with normal plasma and erythrocyte folate levels and in whom erythropoiesis was normoblastic excreted abnormal quantities of FIGLU or urocanic acid or both in the urine. The haematological indices and the folate levels in five patients before and after a remission in disease activity had been induced by ACTH are shown in Table V . The differences in the folate values are not significant for the number of subjects studied.
Follow-up Study
The folate levels in seven patients were assessed 3 months or more after discharge from hospital and compared with the original levels (Table VI,  opposite) .
None of them received folic acid. The follow-up levels in three were lower than the initial levels, but the differences are not statistically significant.
Discussion
The finding of reduced plasma folate levels in the majority of patients with rheumatoid arthritis (Gough and others, 1964; Deller and others, 1966) . Both experimental (Herbert, 1962a) and clinical studies (Hellman, lannotti, and Bertino, 1964; Mollin and Hoffbrand, 1965) indicate that the significance of a low serum folate is best assessed by estimating the erythrocyte folate content and by looking for changes in the bone marrow and haematological indices. The plasma folate level in rheumatoid patients correlated well with the erythrocyte folate content, but the mean erythrocyte/plasma folate ratio in this condition (72:1) is higher than in normal subjects (42:1), indicating a proportionately greater reduction in the plasma folate level compared to that of the erythrocytes. Further, normal erythrocyte folate levels were found in ten cases with reduced plasma folate values ranging from 1-5-2 5 miLg./ml. The reduction in the plasma folate is genuine, and possible inhibitors to L. casei growth, including salicylates, were excluded by experimental trials in this and other studies (Cowan, Hoffbrand, and Mollin, 1966) . This indicates that the plasma folate activity in this condition does not have the same significance as it does in other folate deficient states. Thus, in a series of patients with subnormal serum folate levels due to conditions other than rheumatoid arthritis, Hoffbrand, Newcombe, and Mollin (1966c) found that levels in the unequivocal deficiency range were almost invariably associated with subnormal erythrocyte folate values and with variable degrees of megaloblastic change in the bone marrow.
There is a striking paucity of megaloblastic change in patients with rheumatoid arthritis, who should theoretically have a significant degree of folate deficiency as manifested by subnormal levels of both plasma and erythrocyte folate. Thus, of fourteen such cases only four showed bone marrow changes suggestive of megaloblastosis, and in all of them the changes were classified as early. Of the remaining ten normoblastic cases, three also showed a rapid clearance of folic acid from the plasma. In the series reported by Gough and others (1964) , mild to moderate megaloblastic change was found in only six out of fifteen rheumatoid patients with serum folate levels in the unequivocal deficiency range. Comparison with the other folate deficiency states in this study, and with the series reported by Hoffbrand and others (1966c) shows that megaloblastic change in rheumatoid arthritis is less frequent and, when present, less severe than would be expected from the degree of folate deficiency. It is possible that this is due to the hypochromic nature of the anaemia of rheumatoid arthritis, since it is known that a co-existent impairment of haemoglobin synthesis, e.g. in iron deficiency anaemia or haemoglobinopathy, may mask the overt megaloblastic changes of folate deficiency (Herbert, 1965) .
A relationship has been shown in folate deficiency between FIGLU excretion and serum folate levels. Mollin and Hoffbrand (1965) and Kershaw and Girdwood (1964) found excess FIGLU in the urine of all patients with subnormal serum folate values. However, a dissociation between FIGLU excretion and serum folate values has been shown in vitamin B12 deficiency (Zalusky and Herbert, 1961; Kohn, Mollin, and Rosenbach, 1961; Kershaw and Girdwood, 1964 ); in conditions with neither vitamin B12 or folate deficiency, e.g. liver disease (Carter, Heller, Schnaffer, and Kom, 1961) ; and in malignancy (Noeypatimanond, Watson-Williams, and Israels, 1966) .
In patients with rheumatoid arthritis in whom vitamin B12 deficiency, liver disease, and malignancy had been excluded, no clear relationship was shown between FIGLU excretion and plasma folate values, and no association was shown between FIGLU excretion and erythrocyte folate values. Although there was no relationship between the excretion of histidine metabolites and duration of disease, there was, however, some correlation between the excretion of histidine metabolites and disease activity.
Most observers would agree that increased FIGLU excretion indicates disordered folate metabolism due to either lack, or interference with the function, of the folate co-enzymes or of FIGLU transferase. Folate deficiency may therefore be responsible for the excretion of large quantities of FIGLU in the urine by those rheumatoid patients who had other criteria of the deficiency state, e.g. reduced folate levels and bone marrow changes suggestive of megaloblastic erythropoiesis. The occurrence of a positive FIGLU test, on the other hand, in patients who have a normal folate status may indicate a deficiency of FIGLU transferase, possibly related to disease activity.
Urocanic acid may be the major or only histidine metabolite in the urine of folate deficient subjects (Chanarin and Bennett, 1961; Mohamed and Roberts, 1966) . Since folate co-enzymes are not directly involved in the breakdown of urocanic acid, the mechamism whereby folate deficiency causes a high excretion of this metabolite is obscure. Allen and Whitehead (1965) suggested that the excessive excretion of urocanic acid in protein malnutrition is caused by the disturbed protein metabolism rather than by folate deficiency. Similarly, Hoffbrand, Neale, Hines, and Mollin (1966b) found that patients with low serum albumin levels excreted large quantities of urocanic acid, and that this was returned to normal by intravenous albumin therapy. It is possible, therefore, that increased urocanic acid excretion is related to the reduced serum albumin levels frequently found in rheumatoid patients (Gutman, 1948) . Edozien and Obasi (1965) found a correlation between the excretion of urocanic acid after a histidine load and of xanthurenic acid after a tryptophan load in patients with protein malnutrition. They argued that, since the excretion of xanthurenic acid after a tryptophan load is a test of pyridoxine deficiency, and since the enzyme urocanase has pyridoxal requirements (Gupta and Robinson, 1961) , the excretion of excessive urocanic acid in these patients reflected pyridoxine deficiency. Abnormalities of tryptophan metabolism in patients with rheumatoid arthritis have been reported (Bett, 1962a (Bett, , 1962b , and a relative deficiency of pyridoxine suggested as a cause (Bett, 1966 ). This provides a further possible explanation for the increased urocanic acid excretion and the poor correlation with erythrocyte folate levels in rheumatoid arthritis. Herbert (1962b) and Gough and others (1964) suggested that dietary deficiency might be responsible for the abnormal folate status of patients with rheumatoid arthritis, but they were not able to show any significant difference in the diet of their patients compared to controls. Gough and others (1964) also showed that intestinal absorption of the vitamin was normal in the six megaloblastic cases in their series.
Histories of adequate dietary intake were obtained in all but two cases in the present study, and the intestinal absorption of folic acid was shown to be normal in all of the eighteen cases studied. Further, preliminary (Scott, Porter, Lewis, and Dixon, 1961 ) and the mild haemolytic process in rheumatoid arthritis (Richmond, Alexander, Potter, and Duthie, 1961) may contribute to the folate deficiency. Increased utilization of folic acid during cellular proliferation in the joints of rheumatoid arthritis was suggested by Gough and others (1964) . Hoffbrand, Kremenchuzky, Butterworth, and Mollin (1966a) reported raised serum lactate dehydrogenase (LDH) activity in a number of haematological disorders with some correlation to an associated low serum folate level. It was suggested that increased cell turnover was responsible. In this context it may be relevant that Chalmers (1967) reported an LDH activity in rheumatoid synovial fluid of seven times the serum level. This concept of increased utilization is very possible, but difficult to prove.
Neither the incidence nor the degree of folate deficiency could be related to the duration or severity of the disease. The plasma and erythrocyte levels remained unchanged in five patients in whom a remission of disease activity and a significant rise in haemoglobin concentration were produced by ACTH therapy, and in seven patients who were re-assessed a short time after discharge from hospital and whose disease activity might be expected to have lessened. (3) Alteraciones megaloblasticas en-la medula osea se vieron en un 22 por ciento de los casos. Tanto la incidencia como la severidad de estas alteraciones fueron menores cuando se toma en consideraci6n la intensidad de la carencia de folato.
Summary
